eerences

Cited: LIN ET AL.: 'The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors' PNAS vol.105, no.8, 26 February 2008, USA, pages 3011 - 3016, LI ET AL.: 'Anti-Programmed Death-1 Synergized with Granulocyte Macrophage Colony- Stimulating Factor-Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors' CLINICAL CANCER RESEARCH vol.15, no.5, March 2009, pages 1623 -1634, EP-A1- 1537878, EP-A1- 2172219, WO-A1-2009/089149, WO-A1-2010/077634, WO-A2-2006/133396, US-A1- 2005226883, US-A1- 2009055944, BLANK CHRISTIAN ET AL: "Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro", INTERNATIONAL JOURNAL OF CANCER, UNION INTERNATIONALE CENTRE LE CANCER, vol.119, no.2, 1 July 2006 (2006-07-01), pages 317-327, XP002557386, ISSN: 0020-7136, DOI: 10.1002/IJC.21775, NING LI ET AL: "Potent Systemic Antitumor Immunity Induced by Vaccination with Chemotactic-Prostate Tumor Associated Antigen Gene-Modified Tumor Cell and Blockade of B7-H1", JOURNAL OF CLINICAL IMMUNOLOGY, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NE, vol.27, no.1, 16 December 2006 (2006-12-16), pages 117-130, XP019481374, ISSN: 1573-2592, L. ZHANG ET AL: "PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model", BLOOD, vol. 114, no.8, 20 August 2009 (2009-08-20), pages 1545-1552, XP55053821, ISSN: 0006-4971, DOI: 10.1182/blood-2009-03-206672, PAREKH VRAJESH V ET AL: "PD-1/PD-L Blockade Prevents Anergy Induction and Enhances the Anti-Tumor Activities of Glycolipid-Activated Invariant NKT Cells", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol.182, no.5, 1 March 2009 (2009-03-01) , pages 2816-2826, XP002552134, ISSN: 0022-1767, DOI: 10.4049/JIMMUNOL.0803648, STROME ET AL.: 'B7-H1 Blockade Augments Adoptive t-Cell Immunotherapy for Squamous Cell Carcinoma' CANCER RESEARCH vol.63, 2003, pages 6501 - 6505, NOMI ET AL.: 'Clinical Significance and Therapeutic Potential of the Programmed Death-1 Pathway in Human Pancreatic Cancer' CLINICAL CANCER RESEARCH vol.13, 2007, pages 2151 - 2157, JULIE R BRAHMER ET AL: "Safety and activity of anti-PD-L1 antibody in patients with advanced cancer", NEW ENGLAND JOURNAL OF MEDICINE, THE - NEJM, MASSACHUSETTS MEDICAL SOCIETY, US, vol.366, no.26, 28 June 2012 (2012-06-28), pages 2455-2465, XP002685330, ISSN: 1533-4406, DOI: 10.1056/NEJMOA1200694

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (http://worldwide.espacenet.com) or via the search engine on our website here: https://search.patentstyret.no/